HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Sanofi

People Round-Up: Appointments At Afipa, J&J, Stada, WSMI, And Karo

J&J Consumer has a new chairman, Stada UK gets a permanent head, and Karo names its next CEO. On the association front, France's Afipa and the WSMI elect new leaders.
Appointments International

HHS Rebate Reform: An Air Of Inevitability In Stakeholder Comments

Manufacturers, pharmacy benefit managers and insurers weigh in on the Trump administration’s most significant drug pricing action to date – the HHS Office of Inspector General's proposed rule aimed at eliminating rebates.

Regulation Reimbursement

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets

Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.

Deals Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register